🔥 biotech Hot Theme Analysis

[AZN] AstraZeneca stomach cancer drug doubles survival in late-stage trial

[AMGN] Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.

S-Class [AZN] AstraZeneca says U.S. FDA approves rare kidney disease drug

[QGEN] Qiagen gains on report EQT nearing €9.6B deal

S-Class [QGEN] Qiagen jumps on report EQT in advanced talks to purchase the testing firm

[ARQT] Arcutis Biotherapeutics advances 11% to new 52-week high

[GILD] Gilead hits mid-stage trial success for oral bowel disease therapy